Search

Displaying results 3831 - 3840 of 4584 in total
  1. Drug

    Nitrendipine

    go.drugbank.com/drugs/DB01054
    ApprovedWithdrawn

    Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natri...

  2. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. … Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine.

  3. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.

  4. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.

  5. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  6. Drug

    GRAd-COV2

    go.drugbank.com/drugs/DB16428
    Investigational

    GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].

  7. Drug

    BB-301

    go.drugbank.com/drugs/DB17011
    Investigational

    [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062]

  8. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  9. Drug

    Dexchlorpheniramine

    go.drugbank.com/drugs/DB13679
    Investigational

    It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.

  10. Drug

    1D-myo-inositol 1,4,5-trisphosphate

    go.drugbank.com/drugs/DB03401
    Experimental

    Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane.